These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Other 2020-000419-56 A 12-month, randomized, controlled, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an anti-CD2 monoclonal antibody, TCD601 (sipli... not-yet-due
Other 2021-001680-24 A 60 month, single-arm, proof-of-concept study to induce allogeneic tolerance in deceased donor liver transplant recipients using siplizumab, an anti-CD2 antibody in combination with cyclophosphamide ... not-yet-due
Ongoing 2022-001713-39 A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE) not-yet-due